Orgenesis Inc. Dividend per Share

Dividend per Share of ORGS for past 10 years: annual, quarterly and twelve month trailing (TTM) including Dividend per Share growth rates and interactive chart. Total amount of dividends paid in a quarter or a year divided by the weighted average number of shares outstanding. Can be easily compared to the share price, to determine how much in dividends is an investor getting for each $1 paid for a stock.


Highlights and Quick Summary

  • Dividend per Share for the quarter ending June 29, 2021 was 0.0 (a NaN% decrease compared to previous quarter)
  • Year-over-year quarterly Dividend per Share decreased by NaN%
  • Annual Dividend per Share for 2020 was 0.0 (a NaN% decrease from previous year)
  • Annual Dividend per Share for 2019 was 0.0 (a NaN% decrease from previous year)
  • Annual Dividend per Share for 2018 was 0.0 (a NaN% decrease from previous year)
  • Twelve month Dividend per Share ending June 29, 2021 was 0.0 (a NaN% decrease compared to previous quarter)
  • Twelve month trailing Dividend per Share decreased by NaN% year-over-year
Trailing Dividend per Share for the last four month:
29 Jun '21 30 Mar '21 30 Dec '20 29 Sep '20
0.0 0.0 0.0 0.0
Visit stockrow.com/ORGS for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Dividend per Share of Orgenesis Inc.

Most recent Dividend per Shareof ORGS including historical data for past 10 years.

Interactive Chart of Dividend per Share of Orgenesis Inc.

Orgenesis Inc. Dividend per Share for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 0.0 0.0
2020 0.0 0.0 0.0 0.0 0.0
2019 0.0 0.0 0.0 0.0 0.0
2018 0.0 0.0 0.0 0.0 0.0
2017 0.0 0.0 0.0 0.0 0.0
2016 0.0 0.0 0.0 0.0 0.0 0.0 0.0
2015 0.0 0.0
2014 0.0 0.0
2013 0.0 0.0
2012 0.0 0.0
2011 0.0

Business Profile of Orgenesis Inc.

Sector: Healthcare
Industry: Biotechnology
Orgenesis Inc., a biotech company, focusing on cell and gene therapies (CGTs). The company develops a Point of Care (POCare) platform includes three enabling components: a pipeline of licensed POCare Therapeutics that are processed and produced in closed, automated POCare Technology systems across a collaborative POCare Network. It focuses on autologous therapies, with processes and systems that are developed for each therapy using a closed and automated processing system approach that is validated for compliant production near the patient at their point of care for treatment of the patient. The company's POCare Network brings together patients, doctors, industry partners, research institutes, and hospitals for the clinical development and production of therapies worldwide. Orgenesis Inc. has a collaboration agreement with Savicell Diagnostics Ltd. The company was formerly known as Business Outsourcing Service, Inc. and changed its name to Orgenesis Inc. in August 2011. Orgenesis Inc. was incorporated in 2008 and is based in Germantown, Maryland.